Bormioli Pharma launches “EcoPositive”

At Pharmapack Europe Bormioli Pharma will present the new range of planet-friendly packaging solutions

Bormioli Pharma announces the launch of EcoPositive, a brand new label gathering all the sustainable packaging solutions manufactured by the company, including recycled glass and plastics, bio-based, biodegradable or compostable plastic solutions and advanced polymer products.

The new mark will be presented at the leading industry fair Pharmapack Europe, to be held in Paris, France, May 18-19 (booth A62).

With more than 15 years of research into more responsible packaging solutions for the pharma industry, Bormioli Pharma has introduced to the market – as industrial products – 3 different ranges of low-impact packaging solutions, consistently with 3 different sustainability strategies.

• Regenerate: glass and plastic packaging recycled from first-choice waste collection
• Renew: bioplastic packaging derived from renewable sources
• Reloop: glass and advanced polymer products made from infinitely reusable materials

These approaches will be explained – through a data-driven method – by Roberto Valenti, Head of Materials Development, during the Learning Lab that will be held at Pharmapack on May 19 at 12:50.

“We truly believe sustainability will be the next big thing for the pharmaceutical industry, and we are striving to manufacture pharma-grade quality products that are more responsible towards the environment,” said Andrea Lodetti, CEO of Bormioli Pharma. “This tangible commitment well reflects our company’s purpose to make health a positive practice, accessible to everyone and kind to the planet.”

Sustainability is more and more a key goal for Bormioli Pharma, that has already pledged to use the 50 perce3nt of sustainable raw materials in production by 2025, a goal to which the company is closer year after year – in 2021, this share amounted to 32 percent compared to 16 percent in 2020. The company will also publish its first Integrated Report based on ESG parameters by H1 2022.